RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MULAS O
Collezione AOU Città della Salute di Torino

Items : 11

The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib. in Annals of hematology / Ann Hematol. 2024 Feb;103(2):427-436. doi: 10.1007/s00277-023-05556-0. Epub 2023 Nov 28.

2024
AOU Città della Salute di Torino

Caocci G; La Nasa G; Breccia M; Scalzulli E; Elena C; Giai V; Scaffidi L; Baratè C; Iezza M; Albano F; De Gregorio F; Cattaneo D; Trawinska MM; Loi M; Fozza C; Pregno P; Stagno F; Binotto G; Gozzini A; Orlandi EM; Annunziata M; Bonifacio M; Castagnetti F; Galimberti S; Attolico I; Iurlo A; Abruzzese E; Luciano L; Mulas O; et alii...

Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. in Annals of hematology / Ann Hematol. 2021 Aug;100(8):2005-2014. doi: 10.1007/s00277-020-04392-w. Epub 2021 Jan 3.

2021
AOU Città della Salute di Torino

Cattaneo D; Sicuranza A; Trawinska MM; Pirillo F; Gugliotta G; Stella R; De Gregorio F; Baratè C; Scaffidi L; Simula MP; Efficace F; Luzi D; Fozza C; Albano F; Gozzini A; Bocchia M; Stagno F; Abruzzese E; Pregno P; Binotto G; Castagnetti F; Martino B; Luciano L; Tiribelli M; Galimberti S; Annunziata M; Bonifacio M; Capodanno I; Mulas O; et alii...

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. in Frontiers in oncology / Front Oncol. 2021 Aug 26;11:739171. doi: 10.3389/fonc.2021.739171. eCollection 2021.

2021
AOU Città della Salute di Torino

Rosti G; Saccona F; Mulas O; Levato L; Guella A; Pietrantuono G; La Barba G; Miggiano MC; Abruzzese E; Giai V; De Candia MS; Sanpaolo G; Maggi A; DiTonno P; Reddiconto G; Binotto G; Bocchia M; Galimberti S; Sorà F; Rege-Cambrin G; Fava C; Patriarca A; Capodanno I; Bergamaschi M; Albano F; Scortechini AR; Gozzini A; Pizzuti M; Luciano L; et alii...

Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. in Hematological oncology / Hematol Oncol. 2020 Oct;38(4):607-610. doi: 10.1002/hon.2765. Epub 2020 Jul 23.

2020
AOU Città della Salute di Torino

Mulas O; Caocci G; Annunziata M; Martino B; Luciano L; Castagnetti F; Pregno P; Galimberti S; Albano F; Orlandi EM; Sgherza N; Iurlo A; Bonifacio M; Binotto G; Gozzini A; Bocchia M; Abruzzese E; Fozza C; Simula MP; De Gregorio F; Gugliotta G; Pirillo F; Baratè C; Attolico I; Elena C; Cattaneo D; Scaffidi L; Sicuranza A; Trawinska MM; et alii...

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. in Blood cancer journal / Blood Cancer J. 2020 Jun 8;10(6):66. doi: 10.1038/s41408-020-0333-2.

2020
AOU Città della Salute di Torino

Caocci G; Mulas O; Capodanno I; Abruzzese E; Iurlo A; Luciano L; Albano F; Annunziata M; Tiribelli M; Bonifacio M; Galimberti S; Castagnetti F; Sgherza N; Stagno F; Gozzini A; Orlandi EM; Luzi D; Binotto G; Pregno P; Fozza C; Efficace F; Simula MP; Trawinska MM; Cattaneo D; De Gregorio F; Attolico I; Stella R; Scaffidi L; Baratè C; et alii...

Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. in Annals of hematology / Ann Hematol. 2020 Jul;99(7):1525-1530. doi: 10.1007/s00277-020-04102-6. Epub 2020 May 30.

2020
AOU Città della Salute di Torino

Mulas O; Caocci G; Stagno F; Bonifacio M; Annunziata M; Luciano L; Orlandi EM; Abruzzese E; Sgherza N; Martino B; Albano F; Galimberti S; Pregno P; Bocchia M; Castagnetti F; Tiribelli M; Binotto G; Gozzini A; Capodanno I; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; De Gregorio F; Elena C; Trawinska MM; Cattaneo D; Attolico I; et alii...

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. in International journal of cardiology / Int J Cardiol. 2020 Feb 15;301:163-166. doi: 10.1016/j.ijcard.2019.10.036. Epub 2019 Oct 24.

2020
AOU Città della Salute di Torino

Gugliotta G; Pirillo F; Cattaneo D; Baratè C; Attolico I; Elena C; Scaffidi L; Trawinska MM; De Gregorio F; Simula MP; Stagno F; Fozza C; Bocchia M; Gozzini A; Castagnetti F; Binotto G; Martino B; Sgherza N; Pregno P; Iurlo A; Galimberti S; Albano F; Orlandi EM; Bonifacio M; Abruzzese E; Luciano L; Mulas O; Annunziata M; Caocci G; et alii...

Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. in International journal of cardiology / Int J Cardiol. 2019 Aug 1;288:124-127. doi: 10.1016/j.ijcard.2019.04.051. Epub 2019 Apr 17.

2019
AOU Città della Salute di Torino

Cattaneo D; Elena C; Baratè C; Trawinska MM; Scaffidi L; Fozza C; Martino B; Albano F; Pregno P; Binotto G; Stagno F; Gozzini A; Castagnetti F; Luciano L; Annunziata M; Iurlo A; Orlandi EM; Galimberti S; Abruzzese E; Bonifacio M; Mulas O; Caocci G; Scalzulli E; La Nasa G; Foà R; Breccia M;

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. in Hematological oncology / Hematol Oncol. 2019 Aug;37(3):296-302. doi: 10.1002/hon.2606. Epub 2019 Apr 17.

2019
AOU Città della Salute di Torino

Scaffidi L; Baratè C; Gugliotta G; Albano F; De Gregorio F; Cattaneo D; Trawinska MM; Fozza C; Pregno P; Binotto G; Stagno F; Orlandi EM; Gozzini A; Annunziata M; Bonifacio M; Sgherza N; Galimberti S; Castagnetti F; Attolico I; Iurlo A; Luciano L; Abruzzese E; Mulas O; Caocci G; Elena C; Pirillo F; Scalzulli E; La Nasa G; Foà R; et alii...

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. in American journal of hematology / Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28.

2018
AOU Città della Salute di Torino

Labate C; Cattaneo D; Trawinska MM; Baratè C; Pirillo F; Elena C; Scaffidi L; De Gregorio F; Usala E; Efficace F; Stagno F; Sicuranza A; Bocchia M; Fozza C; Gozzini A; Castagnetti F; Binotto G; Sgherza N; Martino B; Iurlo A; Abruzzese E; Russo Rossi A; Galimberti S; Pregno P; Orlandi EM; Bonifacio M; Luciano L; Annunziata M; Caocci G; et alii...

Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. in Frontiers in oncology / Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.

2018
AO Ordine Mauriziano
AOU Città della Salute di Torino

Pacelli P; Tiribelli M; Annunziata M; Luciano L; Crugnola M; Gozzetti A; Sica S; Caocci G; Baratè C; Mulas O; Defina M; Breccia M; Cattaneo D; Puccetti L; Castagnetti F; Alunni G; Fava C; Sorà F; Martino B; Pregno P; Aprile L; Galimberti S; Gozzini A; Sirianni S; Iurlo A; Abruzzese E; Sicuranza A; Bocchia M; Ferrigno I; et alii...